Drug Article Analysis

Only available on StudyMode
  • Download(s) : 94
  • Published : December 16, 2012
Open Document
Text Preview
DRUG GENERIC NAME: cyclosporine ophthomalic emulsion
The article states the relationship of inflammation and the eyes ability to produce tears may be suppressed due to Chronic Dry Eye. Restasis is a prescription medication indicated to increase tear production in patients with these conditions. The article is correct that ocular inflammation is associated with keratoconjuctivitis sicca. 2. WEAKNESSES OF THE DRUG ADVERTISEMENT

The instructions to the patient are not clearly stated on the article. They are in fine print. Contamination warnings should also be stated on the article instead of in fine print. A person may incorrectly deliver the eye emulsion and could possibly contaminate the medication causing it to no act correctly. 3. DRUG ADVERTISEMENT ADHERENCE TO FDA GUIDELINES:

A. Educate Health Professionals before Beginning Direct-to-Consumer Campaigns •A phone number to contact the FDA (1-800-FDA-1088) and a website (www.fda.gov/medwatch) are given in case of negative side effects you are encouraged to report them. Also a website (restasis30.com) is given and a telephone number (1-877-432-2227) are given to contact Restasis. Instructions should not be used when wearing contact lenses are provided. The producer of Restasis is also given (Allegan). Carcinogenesis, Mutagenesis, and Impairment of Fertility trials are referenced in the article. B. Target Age Appropriate Audience

Prevention magazine( including mid-age and older adults is appropriate audience for the ad addressing Chronic Dry Eye due to eye inflammation, cyclosporine ophthomalic emulsion may be used by adults 17 or older. C. Present the Benefits and the Risks

The benefits of Restasis, an eye emulsion that increases they eyes ability to produce tears were addressed. This product however has the following risks: can cause burning sensation, eye redness, discharge, watery eyes,...
tracking img